Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

18 results about "Amylin" patented technology

Amylin, or islet amyloid polypeptide (IAPP), is a 37-residue peptide hormone. It is cosecreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1 (insulin:amylin). Amylin plays a role in glycemic regulation by slowing gastric emptying and promoting satiety, thereby preventing post-prandial spikes in blood glucose levels.

Modulators of calcitonin receptor and / or amylin receptor activity

PCT designated stage expiredWO2025015268A1Organic active ingredientsNervous disorderCalcitonin receptorCalcitonin
The present application is directed to compounds of formula I which modulate calcitonin receptor and / or amylin receptor activity and can be useful in the treatment of bone, metabolic, cardiovascular, neurodegenerative and other disorders.
Owner:ACONCAGUA BIO INC

Human amylin polypeptide derivative and application thereof

The invention provides a human amylin polypeptide analogue containing non-natural amino acid and a derivative of the human amylin polypeptide analogue. According to the present invention, the human amylin polypeptide derivative obtained by introducing the non-natural amino acid to the N-terminal of the human amylin and modifying with the albumin binding residue can effectively prevent enzymatic degradation and prolong the half-life period, and has characteristics of improved solubility and / or physical stability and / or bioavailability and / or pharmacokinetic properties, the compound can be used for treating obesity and obesity-related diseases.
Owner:HANGZHOU JIUYUAN GENE ENGINEERING CO LTD

Diagnostic marker for Parkinson's disease, application of diagnostic marker and heteropolymer detection method

The invention discloses a diagnostic marker for Parkinson's disease, application of the diagnostic marker and a heteropolymer detection method, and relates to the technical field of biology. The diagnostic marker is a protein heterozygous aggregate in a brain-derived exosome, and the protein heterozygous aggregate comprises alpha-synuclein and amylin. The invention also provides application of a reagent for detecting the diagnostic marker in preparation of a diagnostic product for Parkinson's disease. According to the present invention, the research results show that the important biomarker protein aggregate in the Parkinson's disease diagnosis is not the aggregate simply formed by polymerizing the alpha-Synuclein (aS) protein, but is doped with the other easily aggregated protein-amylin (Amylin); a heteropolymer composed of aS and Amylin is adopted as a biomarker, and the diagnosis efficiency on the Parkinson's disease can be effectively improved.
Owner:THE CHINESE UNIV OF HONG KONG (SHENZHEN) +1

Combination therapy

The present invention relates to methods of treatment using acylated compounds and peptide hormones having dual agonist activity for the GLP-1 (glucagon-like peptide 1) and GLP-2 5 (glucagon-like peptide 2) receptors. In particular, the present invention relates to the administration of a dual GLP-1 / GLP-2 agonist peptide and amylin for modulating body weight and preventing or treating obesity and related conditions.
Owner:ZEALAND PHARMA AS

Compounds for treating diabetes and related conditions

PCT designated stage expiredWO2025042293A1Nervous disorderMetabolism disorderDiseaseAntioxidant
Compounds useful for treating or preventing diabetes and related conditions, and for preventing, inhibiting or reversing amylin-amyloid fibril formation, preventing islets of Langerhans (Beta)-cell death, preventing or reversing the transition from soluble human amylin to insoluble human amylin, preventing and inhibiting or reversing cytotoxic amylin fibril formation. The invention relates to compounds of Formula (I): (I)
Owner:AUCKLAND UNISERVICES LTD +1

Dual amylin calcitonin receptor agonists

PCT designated stage expiredWO2025147628A3Peptide/protein ingredientsCalcitoninsCalcitonin receptorPharmaceutical drug
Peptides that exhibit amylin and calcitonin receptor agonist activity (DACRAs) are provided as well as prodrug derivatives thereof. Analogs having enhanced agonist selectivity for the calcitonin receptor relative to amylin are also provided as well as conjugates of the DACRA peptides with incretin peptides. Pharmaceutical compositions comprising such peptide analogs and therapeutic methods of using such peptide analogs are also provided.
Owner:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP

Petrelintide for use in the treatment of obesity, diabetes or a disease linked to obesity or diabetes, or of reducing body weight, inhibiting weight gain or reducing food intake

The present invention relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, by administering petrelintide at a high dose. The invention also relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, in a human female subject, by administering a non-incretin peptide hormone.
Owner:ZEALAND PHARMA AS

Preparation and application of a kind of nano micelles of brown algae polysaccharide derivatives

The invention discloses a preparation and application of a fucoidan derivative nano-micelle, and relates to the field of marine biomedicine technology. The fucoidan derivative nano-micelle, its raw material fucoidan derivative; the fucoidan derivative is a fucoidan sulfonyl derivative, obtained by chemically connecting the hydroxyl group in the fucoidan structure with the sulfonyl chloride in the structure of 2-(chlorosulfonyl)-1H-indole-1-carboxylic acid tert-butyl ester; the fucoidan is extracted from kelp. The fucoidan derivative nano-micelle prepared by the present invention has stronger amylin aggregation inhibition activity, and the anticoagulant ability is also improved; and it can be used as a good carrier material, with more excellent drug loading capacity and encapsulation rate.
Owner:SHENZHEN DISIP BIOTECHNOLOGY CO LTD

Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for incremental weight loss and management of adverse side effects of weight loss drugs on body composition

The present invention relates to methods for incremental weight loss and to the field of treatment to improve body composition changes and physical function with weight reduction. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), GIP, glucagon, amylin, or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.
Owner:VERU INC

Compounds for treatment of diabetes and related conditions

Compounds useful in the treatment or prevention of diabetes and related conditions and in the prevention, inhibition or reversal of amylin-amyloid fiber formation, the prevention of Langerhans island (beta) cell death, the prevention or reversal of the conversion of soluble human amylin to insoluble human amylin, the prevention and inhibition or reversal of cytotoxic amylin fiber formation. The present invention relates to compounds of formula (I): (I).
Owner:AUCKLAND UNISERVICES LTD +1

Dual agonists of amylin and calcitonin receptors

PendingCO20260011080A2Calcitonin receptorPharmaceutical drug
Peptides exhibiting amylin and calcitonin receptor (DACRA) agonist activity, as well as prodrug derivatives thereof, are provided. Analogues with enhanced agonist selectivity for the calcitonin receptor relative to amylin are also provided, as well as conjugates of the DACRA peptides with incretin peptides. Pharmaceutical compositions comprising the peptide analogues and therapeutic methods of use of the peptide analogues are also provided.
Owner:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP

Modulators of calcitonin receptor and / or amylin receptor activity

PendingCN122270451AOrganic active ingredientsNervous disorderCalcitonin receptorCalcitonin
The present application relates to compounds of Formula I, which modulate calcitonin receptor and / or amylin receptor activity and are useful in the treatment of bone, metabolic, cardiovascular, neurodegenerative and other disorders. I
Owner:ACONCAGUA BIOTECH

Methods and kits for detection of amylin-beta amyloid co-aggregation

Methods for detecting or quantifying amylin-beta amyloid (Aβ) hetero-oligomers (amylin-Aβ aggregate) are provided. Anti-amylin and anti-Aβ antibodies which recognize epitopes that are distinct from high affinity binding sites between amylin peptide and Aβ peptide can be utilized as capture and detection antibodies, respectively, in a sandwich enzyme-linked immunosorbent assay (ELISA) to provide detection and quantification of amylin-Aβ aggregate present in a biological sample, such as blood or brain tissue. Kits useful for the detection and the quantification of amylin-Aβ aggregate are also provided.
Owner:UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION

Dual amylin calcitonin receptor agonists

PCT designated stage expiredWO2025147628A2Peptide/protein ingredientsCalcitoninsCalcitonin receptorPharmaceutical drug
Peptides that exhibit amylin and calcitonin receptor agonist activity (DACRAs) are provided as well as prodrug derivatives thereof. Analogs having enhanced agonist selectivity for the calcitonin receptor relative to amylin are also provided as well as conjugates of the DACRA peptides with incretin peptides. Pharmaceutical compositions comprising such peptide analogs and therapeutic methods of using such peptide analogs are also provided.
Owner:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP

Cyclopeptide-containing polypeptide compound, application thereof and long-acting amylin medicine

The invention relates to the technical field of therapeutic cyclopeptide-containing polypeptides, in particular to a cyclopeptide-containing polypeptide compound, application of the cyclopeptide-containing polypeptide compound and a long-acting amylin medicine. The polypeptide compound containing the cyclic peptide is selected from the following compounds shown in the following structural formula: R < 1-gamma > Glu-Arg-Asp-Gly-Thr-Ala-Thr-Lys-Ala-Thr-Glu-Arg-Leu-Ala-X < 15 >-X < 16 >-X < 17 >-Gln-Arg-Ser-Ser-X < 22 >-X < 23 >-X < 24 >-X < 25 >-X < 26 >-Ser-X < 28 >-Thr-Glu-Val-Gly-Sr-Asn-Thr-{Hyp}-NH2 (Lactm bridge: Asp < 3 >-Lys8), and the structural formula of the polypeptide compound containing the cyclic peptide is shown in the description, (Lactm bridge: Asp3-Lys8) represents an intramolecular lactam bridge formed between side chains of residues of a third amino acid Asp and an eighth amino acid Lys which are counted from an R1 end; r1 represents that R2 is independently selected from any one of a carboxyl group, a carboxylate group, a tetrazolyl group, a phosphate group, a phosphate group, a sulfonic acid group and a sulfonate group; n is any integer from 10 to 24; x < 15 >, X < 16 >, X < 17 >, X < 22 >, X < 23 >, X < 24 >, X < 25 >, X < 26 > and X < 28 > are respectively and independently selected from amino acids. As an amylin drug with a novel structure, the amylin derivative is a multi-target drug and has relatively good biological activity and bioavailability.
Owner:CHENGDU PUKANG WEIXIN BIOTECHNOLOGY CO LTD

Therapeutic combinations of drugs and methods of using them

Provided are therapeutic combinations or formulations of drugs comprising a Glucagon-Like Peptide-1(GLP-1) receptor agonist, a dual GLP-1 / GIP (glucose-dependent insulinotropic peptide) -agonist-, a dual GLP-1 / Glucagon (GCG) receptor agonist, a GLP-1 / GIP / GCG receptor tri-agonist, or an amylin / GLP-1 dual agonist with a monoamine reuptake inhibitor or drugs with complimentary mechanism of actions to a GLP-1 agonists. In alternative embodiments, provided are therapeutic drug combinations for use in treating or ameliorating depression, treatment-resistant depression, hyperphagia (optionally hyperphagia associated with Prader-Willi Syndrome), binge eating disorder, and a substance addiction (wherein the substance addiction comprises addiction to cocaine, an amphetamine, an opioid, alcohol or nicotine).
Owner:CONSYNANCE THERAPEUTICS INC